A Phase 4 interventional study of Apremilast and Placebo in Parapsoriasis, sponsored by Amgen. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial.
This is a Phase 4, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast in subjects with moderate plaque psoriasis. 221 participants were randomized 2 (apremilast):1 (placebo) at approximately 25 sites in the United States. Those randomized to the apremilast treatment group received apremilast 30 mg tablets orally twice daily for 52 weeks. Those randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally twice daily (BID) for 16 weeks. Beginning Week 16, those initially randomized to placebo were switched to receive apremilast 30 mg BID for an additional 36 weeks (52 weeks total).
Study enrolled adult patients with stable moderate plaque psoriasis, who are naïve to systemic psoriasis treatments.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have moderate plaque psoriasis at screening and baseline as defined by
Exclusion Criteria:
or history of malignancy, except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
Drug: Apremilast · Drug: Placebo · Drug: Placebo-Apremilast
Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
Drug: Placebo · Drug: Placebo-Apremilast
Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
Also known as: CC-10004, Otzela
Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
Also known as: Otezla, CC-10004
Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16
BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score. The range of BSA\*sPGA mean percentage change from baseline to week 16 (end of phase) were -100 to 344.4 and -100 to 100 for the placebo and apremilast groups respectively. Higher scores represented worse outcomes.
Time frame: Baseline to Week 16 (end of phase)
Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
Time frame: Baseline to Week 16 (end of phase)
Percentage of Participants Who Achieved a sPGA Score of Clear (0) or Almost Clear (1) at Week 16 From Baseline
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 6-point scale, ranging from 0 (clear) to 5 (very severe), with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are averaged and rounded to the nearest whole number to result in the final sPGA score.
Time frame: Baseline to Week 16 (end of phase)
Percentage of Participants Who Achieved a Clear (0) or Very Mild (1) on Patient Global Assessment (PtGA) Scale at Week 16 From Baseline
The PtGA response rate is defined as the percentage of participants achieving 0 (clear) or 1 (very mild) on the PtGA scale at Week 16. The PtGA is the assessment by the participant of the overall disease severity at the time of evaluation. The PtGA is a 5-point scale ranging from 0 (clear) to 4 (severe).
Time frame: Baseline to Week 16 (end of phase)
Mean Change From Baseline in Pruritus Visual Analog Scale (VAS)
The Pruritus VAS assessment was conducted at the baseline visit and each post-baseline visit. The participant was asked to place a vertical stroke on a 100 mm VAS on which the left-hand boundary (0) represents no itch, and the right-hand boundary (100) represents itch as severe as can be imagined. The distance from the mark to the left-hand boundary will be recorded. The Pruritus VAS score ranges from 0 to 100. Higher scores correspond to more severe symptom.
Time frame: Baseline to Weeks 1 and 16 (end of phase)
Percentage of Participants With Scalp Psoriasis Who Achieved a Clear (0) or Minimal (1) on Scalp Physician's Global Assessment (ScPGA) Scale at Week 16.
The ScPGA assessed scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment. Scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA was restricted to the participants with scalp involvement at baseline.
Time frame: Baseline to Week 16 (end of phase)
Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 16
The TSQM version II is an 11-question self-administered instrument to understand a participation's satisfaction with the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score mean indicates higher satisfaction with treatment.
Time frame: Baseline to Week 16 (end of phase)
Treatment Satisfaction Questionnaire for Medication (TSQM) Version II at Week 52
The TSQM version II is an 11-question self-administered instrument to understand a participants satisfaction on the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.
Time frame: Baseline to week 52
Mean Percentage Change From Baseline in Psoriasis Area Severity Index Score (PASI) at Week 16
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
Time frame: Baseline to Week 16 (end of phase)
Percentage of Participants Who Achieved at Least a 50% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-50 From Baseline at Week 16.
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
Time frame: Baseline to Week 16 (end of phase)
Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-75 From Baseline at Week 16
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
Time frame: Baseline to Week 16 (end of phase)
Mean Percentage Change From Baseline in the Product of BSA (%) x sPGA at Week 52
BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score.
Time frame: Baseline to Week 52
Percentage of Participants With Scalp Psoriasis Who Were Initially Randomized to Apremilast and Maintained the Scalp Physician's Global Assessment (ScPGA) Response From Week 16 to Week 52.
The ScPGA will assess scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment with scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA is restricted to the participants with scalp involvement at baseline.
Time frame: Week 16 to Week 52
Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase
Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
Time frame: From first dose of study drug to Week 16; maximum duration of exposure was 20.1 weeks during placebo controlled phase
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) During the Apremilast-Exposure Phase
Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
Time frame: Date of first dose of apremilast during the placebo controlled phase or date of first dose of apremilast after week 16; overall maximum duration of exposure was 61.5 weeks during apremilast-exposure phase
Participants enrolled into this study were those with moderate plaque psoriasis without prior treatment with systemic agents or biologics and were enrolled across 25 study centers in the United States.
| Milestone | Apremilast | Placebo | Placebo-Apremilast |
|---|---|---|---|
| Started | 148 | 73 | 0 |
| Intent to treat | 147 | 73 | 0 |
| Completed | 121 | 64 | 0 |
| Not completed | 27 | 9 | 0 |
| Withdrew: Adverse event | 5 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 1 | 0 |
| Withdrew: Lost to follow-up | 10 | 4 | 0 |
| Withdrew: Other | 3 | 1 | 0 |
| Milestone | Apremilast | Placebo | Placebo-Apremilast |
|---|---|---|---|
| Started | 121 | 0 | 64 |
| Received treatment | 121 | 0 | 64 |
| Completed | 86 | 0 | 50 |
| Not completed | 35 | 0 | 14 |
| Withdrew: Adverse event | 7 | 0 | 2 |
| Withdrew: Lost to follow-up | 8 | 0 | 6 |
| Withdrew: Withdrawal by subject | 12 | 0 | 4 |
| Withdrew: Lack of efficacy | 8 | 0 | 1 |
| Withdrew: Miscellaneous | 0 | 0 | 1 |
| Milestone | Apremilast | Placebo | Placebo-Apremilast |
|---|---|---|---|
| Started | 81 | 0 | 49 |
| Completed | 80 | 0 | 49 |
| Not completed | 1 | 0 | 0 |
BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score. The range of BSA\*sPGA mean percentage change from baseline to week 16 (end of phase) were -100 to 344.4 and -100 to 100 for the placebo and apremilast groups respectively. Higher scores represented worse outcomes.
| percentage change | Placebo | Apremilast |
|---|---|---|
| Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16 | -10.17 ± 64.043 | -48.07 ± 43.699 |
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
| units on a scale | Placebo | Apremilast |
|---|---|---|
| Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 | -2.4 ± 6.62 | -4.8 ± 5.80 |
The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 6-point scale, ranging from 0 (clear) to 5 (very severe), with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are averaged and rounded to the nearest whole number to result in the final sPGA score.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved a sPGA Score of Clear (0) or Almost Clear (1) at Week 16 From Baseline | 9.6 (4.7 to 18.5) | 30.4 (23.6 to 38.2) |
The PtGA response rate is defined as the percentage of participants achieving 0 (clear) or 1 (very mild) on the PtGA scale at Week 16. The PtGA is the assessment by the participant of the overall disease severity at the time of evaluation. The PtGA is a 5-point scale ranging from 0 (clear) to 4 (severe).
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved a Clear (0) or Very Mild (1) on Patient Global Assessment (PtGA) Scale at Week 16 From Baseline | 20.5 (12.9 to 31.2) | 33.8 (26.7 to 41.7) |
The Pruritus VAS assessment was conducted at the baseline visit and each post-baseline visit. The participant was asked to place a vertical stroke on a 100 mm VAS on which the left-hand boundary (0) represents no itch, and the right-hand boundary (100) represents itch as severe as can be imagined. The distance from the mark to the left-hand boundary will be recorded. The Pruritus VAS score ranges from 0 to 100. Higher scores correspond to more severe symptom.
| units on a scale | Placebo | Apremilast |
|---|---|---|
| Week 1 | -9.6 ± 21.50 | -13.9 ± 20.00 |
| Week 16 | -10.2 ± 30.73 | -19.2 ± 26.09 |
The ScPGA assessed scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment. Scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA was restricted to the participants with scalp involvement at baseline.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants With Scalp Psoriasis Who Achieved a Clear (0) or Minimal (1) on Scalp Physician's Global Assessment (ScPGA) Scale at Week 16. | 38.2 (26.5 to 51.4) | 50.0 (40.9 to 59.1) |
The TSQM version II is an 11-question self-administered instrument to understand a participation's satisfaction with the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score mean indicates higher satisfaction with treatment.
| units on a scale | Placebo | Apremilast |
|---|---|---|
| TSQM-Effectiveness | 38.81 ± 25.843 | 57.25 ± 26.484 |
| TSQM-Side Effects | 75.00 ± 32.428 | 78.50 ± 20.858 |
| TSQM-Convenience | 65.68 ± 16.650 | 66.93 ± 21.216 |
| TSQM-Global Satisfaction | 48.74 ± 25.673 | 63.24 ± 23.624 |
The TSQM version II is an 11-question self-administered instrument to understand a participants satisfaction on the current therapy. The TSQM scale comprises four domains, on which participants evaluate their medication (i.e., effectiveness, side effects, convenience and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.
| units on a scale | Placebo-Apremilast | Apremilast |
|---|---|---|
| TSQM-Effectiveness | 57.68 ± 26.879 | 54.13 ± 26.898 |
| TSQM-Side Effects | 77.29 ± 27.541 | 75.45 ± 24.904 |
| TSQM-Convenience | 72.74 ± 17.222 | 71.76 ± 19.359 |
| TSQM-Global Satisfaction | 59.24 ± 27.941 | 59.92 ± 27.053 |
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
| percentage change | Placebo | Apremilast |
|---|---|---|
| Mean Percentage Change From Baseline in Psoriasis Area Severity Index Score (PASI) at Week 16 | -3.87 ± 79.441 | -40.72 ± 49.523 |
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved at Least a 50% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-50 From Baseline at Week 16. | 24.7 (16.2 to 35.6) | 53.4 (45.4 to 61.2) |
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
| percentage of participants | Placebo | Apremilast |
|---|---|---|
| Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI)-75 From Baseline at Week 16 | 8.2 (3.8 to 16.8) | 21.6 (15.8 to 28.9) |
BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. The sPGA is a 6-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), 5 (very severe) incorporating a separate assessment of the severity of the three primary signs of the plaques of all involved areas: erythema, scaling and plaque elevation with an overall sPGA calculated as (E + I + D)/3. Scores for each assessment are rounded to the nearest whole number to result in the final score.
| percentage change | Placebo-Apremilast | Apremilast |
|---|---|---|
| Mean Percentage Change From Baseline in the Product of BSA (%) x sPGA at Week 52 | -42.23 ± 93.211 | -55.45 ± 44.619 |
The ScPGA will assess scalp involvement, if present at baseline. The 6-point ScPGA scale includes three dimensions (Plaque Thickening, Scaling, and Erythema) and a global assessment with scores range from 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), to 5 (very severe). Analysis of ScPGA is restricted to the participants with scalp involvement at baseline.
| percentage of participants | Apremilast |
|---|---|
| Responder status at Week 16 | 50.0 (40.9 to 59.1) |
| Responder status maintained at Week 52 | 80.4 (68.2 to 88.7) |
Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
| participants | Placebo | Apremilast |
|---|---|---|
| ≥ At Least 1 TEAE | 35 | 92 |
| ≥ 1 Drug-related TEAE | 21 | 71 |
| ≥ At Least 1 Severe TEAE | 1 | 3 |
| ≥ At Least 1 Serious TEAE | 0 | 3 |
| ≥ 1 Serious Drug-related TEAE | 0 | 0 |
| ≥ 1 TEAE leading to drug withdrawal | 3 | 5 |
| ≥ 1 TEAE Leading to drug interruption | 3 | 9 |
| Any TEAE leading to death | 0 | 0 |
Treatment-Emergent Adverse Events (TEAEs) are defined as any AEs that begin or worsen on or after the start of study drug through 28 days after the last dose of study drug or study treatment discontinuation date, whichever was later. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
| participants | Apremilast |
|---|---|
| ≥ At Least 1 TEAE | 142 |
| ≥ 1 Drug-related TEAE | 98 |
| ≥ At Least 1 Severe TEAE | 5 |
| ≥ At Least 1 Serious TEAE | 10 |
| ≥ 1 Serious Drug-related TEAE | 1 |
| ≥ 1 TEAE leading to drug withdrawal | 14 |
| ≥ 1 TEAE Leading to drug interruption | 27 |
| Any TEAE leading to death | 0 |
Collected over Adverse events are reported for the 16-week PBO-controlled and the apremilast extension phase and monitored from the date of the first dose of apremilast to 12 January2017; maximum duration of exposure was 61.5 weeks during apremilast-exposure phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-Controlled Phase: Apremilast (Weeks 0-16) | — | 3/147 (2%) | 73/147 (49.7%) |
| Placebo-Controlled Phase: Placebo (Weeks 0-16) | — | 0/73 (0%) | 23/73 (31.5%) |
| Extension Phase: APR/APR and Placebo/APR (Weeks 0-52) | — | 10/211 (4.7%) | 101/211 (47.9%) |
| Event | Placebo-Controlled Phase: Apremilast (Weeks 0-16) | Placebo-Controlled Phase: Placebo (Weeks 0-16) | Extension Phase: APR/APR and Placebo/APR (Weeks 0-52) |
|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/147 | 0/73 | 1/211 |
| PyelonephritisInfections and infestations | 1/147 | 0/73 | 1/211 |
| Cerebrovascular accidentNervous system disorders | 1/147 | 0/73 | 1/211 |
| NephrolithiasisRenal and urinary disorders | 1/147 | 0/73 | 1/211 |
| DiverticulitisInfections and infestations | 0/147 | 0/73 | 1/211 |
| PneumoniaInfections and infestations | 0/147 | 0/73 | 1/211 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/147 | 0/73 | 1/211 |
| KeratoacanthomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/147 | 0/73 | 1/211 |
| DizzinessNervous system disorders | 0/147 | 0/73 | 1/211 |
| Suicide attemptPsychiatric disorders | 0/147 | 0/73 | 1/211 |
| Event | Placebo-Controlled Phase: Apremilast (Weeks 0-16) | Placebo-Controlled Phase: Placebo (Weeks 0-16) | Extension Phase: APR/APR and Placebo/APR (Weeks 0-52) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 43/147 | 12/73 | 59/211 |
| HeadacheNervous system disorders | 30/147 | 8/73 | 32/211 |
| NauseaGastrointestinal disorders | 26/147 | 7/73 | 40/211 |
| NasopharyngitisInfections and infestations | 5/147 | 2/73 | 22/211 |
| Upper respiratory tract infectionInfections and infestations | 10/147 | 3/73 | 15/211 |
| VomitingGastrointestinal disorders | 9/147 | 2/73 | 12/211 |
| Decreased appetiteMetabolism and nutrition disorders | 6/147 | 4/73 | 11/211 |
The intent to treat (ITT) population consisted all participants who were randomized. Participants were included in the treatment arm which they were randomized into the ITT population.
| Age, Categorical(Participants) | Placebo | Apremilast | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 60 | 120 | 180 |
| >=65 years | 13 | 28 | 41 |
| Age, Continuous(years) | Placebo | Apremilast | Total |
|---|---|---|---|
| Mean | 51.1 ± 13.74 | 48.6 ± 15.41 | 49.4 ± 14.89 |
| Sex: Female, Male(Participants) | Placebo | Apremilast | Total |
|---|---|---|---|
| Female | 32 | 74 | 106 |
| Male | 41 | 74 | 115 |
| Body Surface Area (BSA)(percent affected) | Placebo | Apremilast | Total |
|---|---|---|---|
| Mean | 7.1 ± 1.75 | 7.2 ± 1.61 | 7.2 ± 1.66 |
| Static Physician's Global Assessment (sPGA) Score(Participants) | Placebo | Apremilast | Total |
|---|---|---|---|
| 1 = Almost Clear | 0 | 0 | 0 |
| 2 = Mild | 0 | 0 | 0 |
| 3 = Moderate | 70 | 144 | 214 |
| 4 =Severe | 3 | 3 | 6 |
| 5 = Very Severe | 0 | 0 | 0 |
| Missing | 0 | 1 | 1 |
| Product of BSA and sPGA(psoriasis severity index) | Placebo | Apremilast | Total |
|---|---|---|---|
| Mean | 21.6 ± 5.87 | 21.8 ± 5.17 | 21.7 ± 5.40 |
| Duration of Psoriasis(years) | Placebo | Apremilast | Total |
|---|---|---|---|
| Mean | 12.85 ± 12.350 | 17.02 ± 14.138 | 15.64 ± 13.684 |
| Ethnicity(participants) | Placebo | Apremilast | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 13 | 17 |
| Not Hispanic or Latino | 69 | 134 | 203 |
| Unknown | 0 | 1 | 1 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Apr 2015 to primary completion in Feb 2016, 9 months.
Results were first posted in Jun 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast
Parapsoriasis